Roth Capital raised the firm’s price target on OptimizeRx (OPRX) to $32 from $27 and keeps a Buy rating on the shares. The company reported strong Q3 results and beat its guidance again, while its visibility is clearly much improved after 2024’s weak execution, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target raised to $24 from $20 at Lake Street
- OptimizeRx price target raised to $28 from $18 at B. Riley
- OptimizeRx price target raised to $24 from $23 at Citizens JMP
- OptimizeRx Reports Strong Q3 Growth and Raises Guidance
- OptimizeRx: Strong Financial Performance and Promising Outlook Justify Buy Rating